1384 Novel, immune agonistic CEACAM1/5 antibody (YB-200) demonstrates anti-tumor efficacy and significantly increases B-cell response in syngeneic liver Hepa1-6 tumor microenvironment

Michel Janicot; Katrin Rupalla; Alexej Schmidt; Iris Helfrich; Bernhard B Singer

doi:10.1136/jitc-2022-SITC2022.1384

Log In More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Browse by collection

Archive

Authors

About
Log in More

Log in via Institution
Log in via OpenAthens

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

PDF

Regular and Young Investigator Award Abstracts

Novel Single-Agent Immunotherapies

1384 Novel, immune agonistic CEACAM1/5 antibody (YB-200) demonstrates anti-tumor efficacy and significantly increases B-cell response in syngeneic liver Hepa1-6 tumor microenvironment

Free

	Abstract	Pdf
Nov 2022	154	19
Dec 2022	46	8
Jan 2023	92	12
Feb 2023	106	7
Mar 2023	180	25
Apr 2023	44	3
Total	622	74

Main menu

Online download statistics by month:

Online download statistics by month: November 2022 to April 2023

Log in using your username and password

Main menu

Log in using your username and password

You are here

Online download statistics by month:

Online download statistics by month: November 2022 to April 2023

Read the full text or download the PDF:

Log in using your username and password